Children and Adolescents
Which peptide medicines have FDA-labeled use in adolescents, which do not, and why promoted peptides sold online have no established safety for children and teens.
Content last updated . This page has not been medically reviewed.
Urgent first
If a child or teen may have been given or has injected any peptide product, or has become unwell after an injection, get care now. In the US call 911 for an emergency; US Poison Help is 1-800-222-1222 (see Poison Help by Country). Keep the packaging to show responders. Do not stop a prescribed medicine without talking with the prescriber.One answer does not fit all peptides
Peptide medicines differ widely. Some have studied and labeled uses in adolescents under a specialist's care; many do not; and promoted compounds sold online have no pediatric safety record we could find. This page reads FDA labels on DailyMed and the FDA compounding page. It is information only and does not advise starting, stopping or changing any medicine. Evidence labels: approved medicine, insufficient evidence, Proper evidence not found.Growth-related peptides
Growth-hormone-releasing compounds act on growth pathways. The tesamorelin label's warning about excessive growth in children with open epiphyses (growth plates) shows why this class needs specialist oversight. [4] FDA lists several other growth-hormone-releasing peptides (GHRP-2, GHRP-6, ipamorelin, CJC-1295) among substances with possible safety risks in compounding, citing immunogenicity, impurities and, for some, adverse events in adults or critically ill patients. [5] We did not find pediatric safety data for them in the sources read. Proper evidence not found; see Growth-Hormone-Releasing Peptides.Promoted peptides: BPC-157 and others
A PubMed search on 2026-10-22 for BPC-157 together with children, pediatric or adolescents returned 9 records; by their titles, none was a pediatric human study (the titles named rat studies and reviews). [6] A 2026 systematic review of human BPC-157 evidence found three small studies (30 participants) and rated certainty very low. [7] Proper evidence not found for safety in children. FDA says it lacks enough information to know whether BPC-157 would cause harm in humans. [5]Why youth are a special concern with online products
Products sold online "for research" are not made or checked for human use, and testing of such products has found wrong strength, endotoxin and toxic metals. [8][9] FDA has warned companies selling GLP-1-class products falsely labeled "for research purposes." [10] In a 2026 case report an 18-year-old with no medical history developed a serious metabolic complication after starting semaglutide bought online; the authors note uncertain dosing and purity. A single case cannot show cause. [11] See Mislabeling, Incorrect Strength and Degradation Products.For parents and teens
Appearance- and performance-focused social media can promote peptides with strong claims. See How to Evaluate Peptide Claims and Clinic Marketing and Children and Teens in natural remedy safety. Talk with a pediatrician or other licensed clinician about any peptide product. This is not medical advice.Frequently asked questions
Are peptide medicines approved for teenagers?
Some are, for specific uses: the US labels for Wegovy and Saxenda include patients 12 years and older with obesity under specified conditions. [1][2]
Is Zepbound approved for children?
The US label read on 2026-10-22 says safety and effectiveness have not been established in pediatric patients. [3]
Is tesamorelin used in children?
Its label says it is not indicated for pediatric patients and may cause excessive growth in those with open growth plates. [4]
Is BPC-157 safe for teens?
Proper evidence not found. [6]
What should a parent do if a teen has bought peptides online?
Talk with the teen and a clinician. In an emergency call 911 (US); Poison Help is 1-800-222-1222.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Approved peptide medicines: what the labels say about age
| Medicine (active ingredient) | Pediatric statement in the US label read |
|---|---|
| Wegovy injection (semaglutide) | Safety and effectiveness established for weight reduction in patients 12 years and older with obesity, supported by a 68-week placebo-controlled trial of 201 patients; adolescents had more gallbladder problems, low blood pressure, rash and hives than adults [1] |
| Saxenda (liraglutide) | Established in patients 12 years and older with body weight above 60 kg and an initial BMI of 30 or more (adult cut-offs); supported by a 56-week trial of 251 patients aged 12 to 17; more episodes of hypoglycemia than placebo and one pancreatitis event; not established under age 12 [2] |
| Zepbound (tirzepatide) | Safety and effectiveness not established in pediatric patients (label read 2026-10-22) [3] |
| Egrifta WR (tesamorelin) | Not established in pediatric patients; in children with open growth plates it may cause linear growth acceleration and excessive growth; not indicated for pediatric patients [4] |
These are label statements about labeled indications used under medical supervision, with the label's own boundaries. The Wegovy label says adolescents' side effects were generally similar to adults, with the exceptions above. [1] Labels can change, and other countries' regulators may say different things; we did not verify other jurisdictions here. A quick summary: an approved adolescent use for one product does not mean another peptide, or a compounded copy, is suitable for a child.
References
- DailyMed (U.S. National Library of Medicine), WEGOVY (semaglutide) prescribing information, Novo Nordisk, label revised 06/2026. Read 2026-10-22.
- DailyMed (U.S. National Library of Medicine), SAXENDA (liraglutide) prescribing information, Novo Nordisk. Read 2026-10-22.
- DailyMed (U.S. National Library of Medicine), ZEPBOUND (tirzepatide) prescribing information, Eli Lilly. Read 2026-10-22.
- DailyMed (U.S. National Library of Medicine), EGRIFTA WR (tesamorelin) prescribing information, Theratechnologies. Read 2026-10-22.
- U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). Read 2026-10-22.
- PubMed search: BPC-157 AND (children OR pediatric OR adolescents). Searched 2026-10-22 via NCBI E-utilities; 9 records returned, titles screened. Read 2026-10-22.
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety, Acta Orthop Belg 2026. Read 2026-10-22 (abstract).
- Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription, J Med Internet Res 2024. Read 2026-10-22 (abstract).
- Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market, Talanta 2018. Read 2026-10-22 (abstract).
- U.S. Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026). Read 2026-10-22.
- Euglycemic ketoacidosis following the use of counterfeit semaglutide for weight loss (case report), Cureus 2026. Read 2026-10-22 (abstract).
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.